



# REVISTA BRASILEIRA DE ANESTESIOLOGIA

Official Publication of the Brazilian Society of Anesthesiology  
[www.sba.com.br](http://www.sba.com.br)



## LETTER TO THE EDITOR

### Reporting potential conflicts of interest



### Comunicando potenciais conflitos de interesse

Dear Editor,

It was with surprise that I saw recently the paper of Sadeghi et al.<sup>1</sup> published in your journal with me as a co-author. As a matter of fact, I was involved in the study design, data analysis and writing of the manuscript. However, I was not involved in the submission process of the manuscript to your journal which explains why my conflict of interest statement is lacking in the current publication. This is highly unfortunate since openly declaring all potential conflicts of interest are of prime importance to me. I therefore declare in this letter all my conflicts of interests.

Dr. Spahn's academic department is receiving grant support from the Swiss National Science Foundation, Berne, Switzerland (grant numbers: 100 014.138545/1, 33CM30.124117, 33CM30.140339 and 406440-131268), the Ministry of Health (Gesundheitsdirektion) of the Canton of Zurich, Switzerland for Highly Specialized Medicine, the Swiss Society of Anesthesiology and Reanimation (SGAR), Berne, Switzerland (no grant numbers attributed), the Swiss Foundation for Anesthesia Research, Zurich, Switzerland (no grant numbers attributed), Bundesprogramm Chancengleichheit, Berne, Switzerland (no grant numbers attributed), CSL Behring, Berne, Switzerland (no grant numbers attributed), Vifor SA, Villars-sur-Glâne, Switzerland (no grant numbers attributed).

Dr. Spahn was the chairman of the ABC Faculty and is the co-chairman of the ABC-Trauma Faculty, which both are managed by Physicians World Europe GmbH, Mannheim, Germany and sponsored by unrestricted educational grants from Novo Nordisk Health Care AG, Zurich, Switzerland, CSL Behring GmbH, Marburg, Germany and LFB Biomédicaments, Courtaboeuf Cedex, France.

In the past 5 years, Dr. Spahn has received honoraria or travel support for consulting or lecturing from the following companies: Abbott AG, Baar, Switzerland, AMGEN GmbH, Munich, Germany, AstraZeneca AG, Zug, Switzerland, Bayer (Schweiz) AG, Zürich, Switzerland, Baxter AG, Volketswil, Switzerland, Baxter S.p.A., Roma, Italy, B. Braun Melsungen AG, Melsungen, Germany, Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Bristol-Myers-Squibb, Rueil-Malmaison Cedex, France and Baar, Switzerland, CSL Behring GmbH, Hattersheim am Main, Germany and Berne, Switzerland, Curacyte AG, Munich, Germany, Ethicon Biosurgery, Sommerville, New Jersey, USA, Fresenius SE, Bad Homburg v.d.H., Germany, Galenica AG, Bern, Switzerland (including Vifor SA, Villars-sur-Glâne, Switzerland), GlaxoSmithKline GmbH & Co. KG, Hamburg, Germany, Janssen-Cilag AG, Baar, Switzerland, Janssen-Cilag EMEA, Beerse, Belgium, Merck Sharp & Dohme AG, Luzern, Switzerland, Novo Nordisk A/S, Bagsvård, Denmark, Octapharma AG, Lachen, Switzerland, Organon AG, Pfäffikon/SZ, Switzerland, Oxygen Biotherapeutics, Costa Mesa, CA, Photonics Healthcare GmbH, Munich, Germany, ratiopharm Arzneimittel Vertriebs-GmbH, Vienna, Austria, Roche Diagnostics International Ltd, Reinach, Switzerland, Roche Pharma (Schweiz) AG, Reinach, Switzerland, Schering-Plough International, Inc., Kenilworth, New Jersey, USA, Tem International GmbH, Munich, Germany, Verum Diagnostica GmbH, Munich, Germany, Vifor Pharma Deutschland GmbH, Munich, Germany, Vifor Pharma Österreich GmbH, Vienna, Austria, Vifor (International) AG, St. Gallen, Switzerland.

The only relationship with the research presented in the paper of Sadeghi et al.<sup>1</sup> may be the fact that I met the senior author of the paper, Doctor Ali Movafegh, at a CSL Behring sponsored educational event and that CSL Behring is the manufacturer of the fibrinogen used in this study. However, CSL Behring had no involvement in this study and the fibrinogen used in the study was regularly purchased by the Tehran University of Medical Sciences.

DOI of original article: <http://dx.doi.org/10.1016/j.bjane.2013.10.010>

<http://dx.doi.org/10.1016/j.bjane.2014.09.008>

0104-0014/© 2015 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. All rights reserved.

## Conflicts of interest

The author declares no conflicts of interest.

## Reference

1. Sadeghi M, Atefyekta R, Azimaraghi O, et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery. *Rev Bras Anesthesiol.* 2014;64:253–7.

Donat R. Spahn

*Institute of Anesthesiology, Section Head Medical Anesthesiology, Intensive Care Medicine, OR Management, University of Zurich and University Hospital Zurich, Zurich, Switzerland*

*E-mail: [donat.spahn@usz.ch](mailto:donat.spahn@usz.ch)*

Available online 7 March 2015